| Literature DB >> 32745604 |
Sourena Sharifkashani1, Melika Arab Bafrani2, Alireza Soltani Khaboushan1, Marzieh Pirzadeh3, Ali Kheirandish4, Hanie Yavarpour Bali3, Amirhossein Hessami5, Amene Saghazadeh6, Nima Rezaei7.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a beta coronavirus that uses the human angiotensin-converting enzyme 2 (ACE2) receptor as a point of entry. The present review discusses the origin and structure of the virus and its mechanism of cell entry followed by the therapeutic potentials of strategies directed towards SARS-CoV2-ACE2 binding, the renin-angiotensin system, and the kinin-kallikrein system. SARS-CoV2-ACE2 binding-directed approaches mainly consist of targeting receptor binding domain, ACE2 blockers, soluble ACE2, and host protease inhibitors. In conclusion, blocking or manipulating the SARS-CoV2-ACE2 binding interface perhaps offers the best tactic against the virus that should be treated as a fundamental subject of future research.Entities:
Keywords: ACE2; COVID-19; Origin; SARS-CoV2; Therapeutic; Transmission
Mesh:
Substances:
Year: 2020 PMID: 32745604 DOI: 10.1016/j.ejphar.2020.173455
Source DB: PubMed Journal: Eur J Pharmacol ISSN: 0014-2999 Impact factor: 4.432